9,870 Kymera Therapeutics, Inc. $KYMR Shares Acquired by Kornitzer Capital Management Inc. KS

Kornitzer Capital Management Inc. KS grew its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 47.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,490 shares of the company’s stock after buying an additional 9,870 shares during the quarter. Kornitzer Capital Management Inc. KS’s holdings in Kymera Therapeutics were worth $3,408,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the business. AlphaCentric Advisors LLC boosted its stake in shares of Kymera Therapeutics by 6.4% in the third quarter. AlphaCentric Advisors LLC now owns 5,729 shares of the company’s stock valued at $640,000 after buying an additional 344 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. acquired a new position in Kymera Therapeutics during the third quarter worth $514,000. China Universal Asset Management Co. Ltd. raised its position in Kymera Therapeutics by 20.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 15,812 shares of the company’s stock worth $1,747,000 after acquiring an additional 2,721 shares in the last quarter. Sterling Capital Management LLC raised its position in Kymera Therapeutics by 378.6% in the third quarter. Sterling Capital Management LLC now owns 1,919 shares of the company’s stock worth $215,000 after acquiring an additional 1,518 shares in the last quarter. Finally, Inspire Investing LLC purchased a new position in Kymera Therapeutics in the third quarter worth $482,000.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on KYMR shares. Wolfe Research raised Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $180.00 target price for the company in a report on Thursday, September 10th. Citigroup upped their price target on shares of Kymera Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a research note on Monday, October 5th. Bank of America upped their price target on shares of Kymera Therapeutics from $123.00 to $144.00 and gave the stock a “buy” rating in a research note on Monday, September 14th. Wall Street Zen downgraded shares of Kymera Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 31st. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Kymera Therapeutics in a research note on Thursday, July 30th. They issued a “hold” rating and a $120.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $139.16.

View Our Latest Stock Report on KYMR

Kymera Therapeutics Price Performance

Shares of NASDAQ:KYMR opened at $131.73 on Monday. The business’s 50 day simple moving average is $115.68 and its 200-day simple moving average is $97.81. The firm has a market capitalization of $11.25 billion, a price-to-earnings ratio of -36.39 and a beta of 2.04. Kymera Therapeutics, Inc. has a 12 month low of $56.75 and a 12 month high of $138.00.

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.06). Kymera Therapeutics had a negative return on equity of 22.39% and a negative net margin of 285.33%. The firm had revenue of $1.35 million during the quarter, compared to analyst estimates of $3.28 million. During the same quarter in the prior year, the company earned ($0.94) EPS. The business’s revenue was up .0% on a year-over-year basis. On average, equities analysts anticipate that Kymera Therapeutics, Inc. will post -3.88 earnings per share for the current year.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, CEO Nello Mainolfi sold 30,000 shares of the business’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the sale, the chief executive officer directly owned 666,568 shares in the company, valued at approximately $75,855,438.40. The trade was a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Brian Adams sold 6,371 shares of the business’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $116.83, for a total value of $744,323.93. Following the sale, the insider owned 50,254 shares in the company, valued at approximately $5,871,174.82. The trade was a 11.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 15.98% of the company’s stock.

Kymera Therapeutics Profile

(Free Report)

Kymera Therapeutics, Inc is a clinical-stage biotechnology company developing medicines that selectively remove disease-causing proteins from cells. Its approach, known as targeted protein degradation, uses the body’s natural protein-disposal system and is designed to address targets that may be difficult to reach with conventional drugs.

The company’s research and development programs include small-molecule protein degraders for conditions involving immune and inflammatory pathways, as well as cancer.

See Also

Want to see what other hedge funds are holding KYMR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report).

Institutional Ownership by Quarter for Kymera Therapeutics (NASDAQ:KYMR)

Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.